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Mutationsofmitochondrial DNAare linked tomanyhumandiseases. Despite the identificationof a large number
ofvariants in themitochondriallyencodedrRNA(mt-rRNA)genes, theevidencesupportingtheirpathogenicity is,
atbest,circumstantial.Establishing thepathogenicityof thesevariations isofmajordiagnostic importance.Here,
weaimtoestimatethedisruptiveeffectofmt-rRNAvariationsonthefunctionof themitochondrial ribosome. Inthe
absence of direct biochemicalmethods to study the effect ofmt-rRNA variations, we relied on the universal con-
servationof the rRNAfold to infer theirdisruptivepotential.Ourmethod,namedheterologous inferential analysis
or HIA, combines conservational information with functional and structural data obtained from heterologous
ribosomal sources. Thus, HIA’s predictive power is superior to the traditional reliance on simple conservation
indexes. By using HIA, we have been able to evaluate the disruptive potential for a subset of uncharacterized
12S mt-rRNA variations. Our analysis revealed the existence of variations in the rRNA component of the
humanmitoribosomewithdifferentdegreesof disruptivepower. In caseswhere sufficient information regarding
the genetic and pathological manifestation of themitochondrial phenotype is available, HIA data can be used to
predict the pathogenicity of mt-rRNA mutations. In other cases, HIA analysis will allow the prioritization of
variants for additional investigation. Eventually, HIA-inspired analysis of potentially pathogenic mt-rRNA varia-
tions, in the context of a scoring system specifically designed for these variants, could lead to a powerful
diagnostic tool.
INTRODUCTION
Currently, more than 550 mitochondrial DNA (mtDNA) mutations
and sequence variants have been associated with human disease
(1). Since it has been estimated that the minimal prevalence of clin-
ically manifesting mtDNA disease in adults is 1 in 10 000 (2),
establishing whether mtDNA mutations are pathogenic is of
major importance for genetic counseling and patient support.
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Whilst important, the assignment of pathogenicity to mtDNA
mutations is a difficult task. This is in no small part due to high
levels of mtDNA variation inhuman populations and the extremely
heterogeneous clinical presentations of many known mtDNA
mutations. Due to these and other difficulties, the evidence for
pathogenicity has been rather weak in some cases, especially in
the contextof rRNA variation. In fact, someauthorshavesuggested
that a number of these associations might be erroneous (3–7).
DiMauro and Schon (8) were the first to describe criteria for the
identification of mutations in mtDNA linked to disease. Since then,
our understanding of the elements associated with pathogenicity
has substantially changed. For example, the first element cited by
DiMauro and Schon for the identification of pathogenic mutations
was that the variant must be heteroplasmic (i.e. the mutated and
wild-type variants co-existing in the cells of the affected tissues).
More recently, it has become appreciated that certain pathogenic
variants may exist as homoplasmic mutations with variable
degrees of penetrance (9). These changes in our appreciation of
the elements required for pathogenicity, together with the fact
that the data available in databases has grown enormously, makes
it imperative tofindanewframeworkfor theanalysisofmitochond-
rially encoded rRNA (mt-rRNA) variations. The emergence of
scoring systems has provided a much needed tool for the evaluation
of certain categories of mtDNA mutations and should provide guid-
ance to future research on mt-rRNA variation (6,7,10–12).
With all probability, an important subset of pathogenic
mtDNA variations map to the mt-rRNA genes; however, they
remain the most difficult genes in which to confirm the pathogen-
icity of an mtDNA variant. Since the mitochondrial ribosome
(mitoribosome) translates all 13 proteins encoded by the mito-
chondrial genome, mutations leading to ribosome dysfunction
should result in a respiratory chain defect and, therefore, cause
mitochondrial disease. This prediction was confirmed by the
identification of alterations in the nuclear and mitochondrial
genome that affect the mitochondrial translational machinery.
For example, a small number of highly deleterious mutations
have been identified in the nuclear genes encoding protein com-
ponents of mitoribosomes, mitochondrial translation factors and
elements of the apparatus involved in the maturation of mitoribo-
somes (13–20). The severity of these mutations clearly indicates
that interfering with mitochondrial protein synthesis can lead to
highly deleterious phenotypes.Not surprisingly, deleterious muta-
tions have also been identified in the rRNA component of the
mitoribosome. Two such mutations, 908A.G (m.1555A.G)
and 847C.U (m.1494C.T), are well-known causes of hearing
loss (21). In addition, there is a large list of other mt-rRNA muta-
tions whose pathogenic role is yet to be convincingly proven.
Thus, despite the identification of base substitutions in the
mt-rRNA of patients, the evidence supporting the pathogenicity
of mt-rRNA variations is, at best, circumstantial, except for the
two cases mentioned above. The reasons for this are many. First,
ascertaining the magnitude of the actual biochemical defect
caused by such variations is often complicated by incomplete
penetrance, as well as by the possible existence of nuclear modi-
fiers. Secondly, the existence of numerous human haplogroups
further complicates the correct assignment of mutations, as the
penetrance of some variants might change in different genetic con-
texts (22). Thirdly, the intractability of the mitochondrial transla-
tion apparatus and the lack of methods for the manipulation of
the mitochondrial genome make it impossible to test the effect of
these mutations directly. Finally, all of this is complicated by the
lack of agreement among authors on the criteria that should be
used to evaluate pathogenicity in the context of mt-rRNA muta-
tions (5,23). For all these reasons, it is imperative that a robust
system is devised that allows the assessment of the biochemical
defect caused by mt-rRNA mutations.
Scoring systems have been developed and validated for the ana-
lysisofthepotentialpathogenicityofbothmt-tRNAandmitochond-
rially encoded complex I subunits (6,7,10–12). The existence of a
substantial number of known mutations and gold-standard experi-
mental procedures, including biochemical and transmitochondrial-
cybrid evidence, were important in developing these scoring
systems. Unfortunately, these elements are largely lacking in the
case of mt-rRNA variations. To fill this void, we propose taking ad-
vantage of the universal conservation of the rRNA structure (24) in
order to assess the disruptive potential of mt-rRNA variations. Our
approach, which we have named heterologous inferential analysis
(HIA) predicts the structural and/or functional role of a particular
mt-rRNA residue by extrapolating conclusions drawn from evi-
dence pertaining to its structurally equivalent position in a heterol-
ogous ribosome. HIA is used in this paper to analyze a subset of
extremely rare variations mapping to the small ribosomal subunit
(SSU) of the mitoribosome, which are suspected to be associated
with a respiratory chain defect. Our goal is to establish whether
these mt-rRNA variations have a potentially disruptive effect on
the function of the mitoribosome. While HIA alone cannot, in
most cases, be used to establish pathogenicity beyond doubt, we
believe that it constitutes an important first step toward building a
scoring system with clinical relevance that can be used to predict
the pathogenic potential of mt-rRNA variations. At the same time,
HIA’s predictions will allow the prioritization of variants for add-
itional functional investigation. Additionally, for certain mt-rRNA
mutations for which sufficient information regarding the genetic
and pathological manifestation of the mutations are available,
HIA data can be used to predict their pathogenicity.
RESULTS
Our search through the literature for mt-12S rRNA variations
possibly associated with disruption of mitochondrial function,
as defined in the section Materials and Methods, resulted in the
identification of 161 different variations, corresponding to 152
different sites, almost 16% of the molecule (not shown). Evalu-
ation of evidence used to identify mtDNA mutations in other
mtDNA genes indicates that the absence of the variant in controls
is important evidence of pathogenicity. In the absence of proper
experimental controls in most of the cases studied here, we
turned to the GenBank and Phylotree databases to screen for ex-
tremely rare variations, i.e. variations with zero appearances in
these databases. While we know this criteria would excluded
the known pathogenic variants, 1555A.G with 29 appearances
and 1494C.T with three appearances, it was hoped that such a
criterion would identify a group of variants most likely to yield
pathogenic or potentially pathogenic mutations.
Correlation between phylogenetic conservation and the
distribution of variations in mt-12S rRNA
The accuracy of phylogeny-driven algorithms for the prediction
of rRNA structure has been amply demonstrated (24). Therefore,
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we reasoned that the universal conservation of the rRNA fold
must be central to any inferential attempt to ascertain the poten-
tially disruptive effect of mutations in mt-rRNA. Figure 1A
shows the secondary structure map of the human 12S rRNA
with all domains and helices numbered according to the nomen-
clature used for the bacterial 16S rRNA, shown in Figure 1B
(25). Figure 1C shows the three dimensional structure of the
Escherichia coli SSU with landmarks indicated (accession
code 2I2P). Despite the loss of many peripheral RNA segments
in the human 12S rRNA, the overall fold is clearly conserved
(Fig. 1A and B), thus allowing the identification of equivalent
residues in both structures. Only for positions lying in areas of
little structural homology does the identification of heterologous
structural equivalents become impossible.
The aforementioned idea that rare variations might be good
candidates for pathogenic mutations would require a non-
random distribution of variations in the MT-RNR1gene, i.e.
that an inverse correlation exists between phylogenetic conser-
vation and the number of variations per residue. However, our
analysis of near 18 000 complete sequences of the human
mt-genome currently deposited in GenBank showed a high
prevalence of mt-12S rRNA sites carrying variations, i.e.
27.6% of all sites (Table 1). This prompted us to consider
whether such a correlation between phylogenetic conservation
and the distribution of variations per mt-12S rRNA residue actu-
ally exists. Conservation values Cvs for SSU rRNA residues have
been calculated by using 8513 SSU rRNA sequences from all
three phylogenetic domains, Eubacteria, Archaea and Eucarya
Figure 1. (A and B) SSU secondary-structure maps. The secondary-structure map of the human mt-12S rRNA is shown in (A). Helices numbered according to the
E. coli secondary structure model, shown in B. (C) Three-dimensional structure of theE. coliSSU with landmarks indicated. (D) Percentage of mt-12S rRNA positions
carrying GenBank variations within each Cv bin. Cv bins were defined as described at the Comparative RNA Web (CRW) Site (25,26).Back row: per-bin percentage of
sites with GenBank variations, relative to the total number of residues in each Cv bin. Middle row: per-bin percentage of sites with GenBank variations, relative to
the total number of mt-12S rRNA sites with variations present in GenBank. Front row: normalized, per-bin percentage of sites with GenBank variations, relative
to the normalized total number of mt-12S rRNA sites with such variations (normalization is to the Cv bin with the highest number of sites, i.e.
1. Cv ≥ 0; the normalized values used for these calculations are shown in Table 1). X axis: Cv bins. Y axis: percentage value. (E) Distribution of mt-12S rRNA
GenBank variations per Cv bin. The distribution is shown as the number of GenBank variations per site within each Cv bin (two back rows, see main text for calculation
details); as the per-bin percentage of variations, relative to the total number of mt-12S rRNA variations present in GenBank (two middle rows); and as the per-bin,
normalized percentage of variations, relative to the normalized total number of mt-12S rRNA variations with such variations (normalization as in D). Odd rows: as
adjacent even row but corrected after discarding the outlier residue 180A (m.827A) (see main text. Only shown for most conserved bin).Xaxis: Cv bins.Yaxis: number
of variations per site (two back rows), percentage value (four front rows).
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(including nuclear, mitochondria and chloroplast sequences) (25).
According to the authors, 100% conservation would yield a Cv of
2, 90% conservation would result in Cvs around 1.5, 60–80% con-
servation in Cvs near 1.0, 40–50% conservation in values
approaching 0.5 and total lack of conservation in values below 0
(26). Since Cvs constitute measurements of universal rRNA con-
servation and, thus, should have relevance in all ribosomal
systems, including organellar ones, one would expect that the
number of variations at every position should correlate with
their Cv. Accordingly, positions with higher Cvs, i.e. more
highly conserved, would display a lower number of variations
than positions with lower Cvs. To test this hypothesis we aligned
the 954 residues of mt-12S rRNA and the 1542 residues of
E. coli 16S rRNA by using the secondary-structure maps as a ref-
erence (not shown). As a source of mt-12S rRNA variations we
used the GenBank database. After extracting all the variation
data for every mt-12S rRNA position, we compared these data
to the calculated Cvs for the same position.
When the percentage of mt-12S rRNA positions carrying
GenBank variations in every Cv bin is plotted, a clear picture
emerges. Only 4 of 115 virtually universally conserved residues
carried variations, corresponding to 3.48% of all such sites
(Table 1 and Fig. 1D, back row). The percentage of sites carrying
variations increases sharply as we move into less conserved cat-
egories. By definition, the category of residues with Cvs , 0 is
not well represented within mt-12S rRNA (with only 13
aligned residues in this bin). Thus, this bin must be considered
as a non-significant element of the analysis. Instead, 161 non-
conserved mt-12S rRNA residues were placed in an additional
category, named ‘not aligned’ and the associated percentage of
variations was calculated. Strikingly, almost 53% of the residues
in this category carried variations, an observation that is in clear
agreement with our hypothesis of a non-random distribution of
variations in human mtDNA. Also shown in Figure 1D is the per-
centage of sites with variations within each bin, relative to the
total number of such sites in the whole mt-12S rRNA (middle
row). Additionally, to account for the different bin sizes, we nor-
malized the number of sites with variations in every bin to the bin
with the highest number of such sites, namely the 1 . Cv ≥ 0 bin
(Table 1). These data were used to calculate a normalized per-
centage of sites with variations per bin (front row of Fig. 1D).
Again, the normalized data clearly follows a trend that is consist-
ent with our hypothesis, i.e. the existence of an inverse correlation
exists between phylogenetic conservation and the number of
variations per residue. The trend is particularly strong for the
bins with highest (2. Cv ≥ 1.9 and 1.9. Cv ≥ 1.5) and
lowest (‘not aligned’) Cvs values.
We also investigated the correlation between the total number
of variations recorded in GenBank (all possible variations per
site were taken into account for this purpose) and Cv values.
This was done by dividing the total number of variations
recorded at all sites within a Cv bin by the number of sites in
the bin (Fig. 1E, rows 5 and 6). The two most conserved categor-
ies clearly display the lowest numbers of variations per site, i.e.
2.90 variations/site for the most conserved bin (2.Cv ≥ 1.9)
and 1.05 variations/site for the next bin (1.9. Cv ≥ 1.5)
(Fig. 1E, 6th row). Notably, a single residue from the nearly in-
variant bin (2. Cv ≥ 1.9), namely position A827, accounts for
330 out of the 333 variations in the bin (Table 1). When this
outlier is excluded from the calculations, the number of varia-
tions per site for the nearly invariant bin becomes 0.03
(Fig. 1E, 5th row from the front), in agreement with the extreme-
ly high conservation of the residues in this bin. Similarly to
Figure 1D, the number of variations per site increases sharply as
we move into the less conserved bins, reaching a maximum at
the ‘not-aligned’ bin (41.40 variations/site). When the total
number of variations per bin is plotted as a percentage of the
total number of mt-12S rRNA variations recorded in GenBank,
the two most conserved bins account for only 3.38% of the total
number of variations (1.11% if the aforementioned outlier is
excluded). On the contrary, the ‘not-aligned’ bin accounts for
.45% of the variations (Fig. 1E, 3rd and 4th rows). A similar
trend is observed after normalization of the percentages to
account for bin size (Fig. 1E, 1st and 2nd rows). Again, the data
shown in Figure 1E are in agreement with our hypothesis.
In summary, our comparison of phylogenetically derived data
on SSU rRNA conservation and the human mtDNA records cur-
rently available in GenBank clearly shows that the distribution of
variations in mt-12S rRNA is non-random. This distribution
shows a strong inverse correlation with the phylogenetically
derived conservation value, Cv. In addition to confirming the
strength of comparative methods for the study of rRNA struc-
ture, these results validate the use of the GenBank and Phylotree
databases as criteria for the identification of extremely rare var-
iations. Doing this, one would expect that an important propor-
tion of such variations could map to highly conserved residues
with large disruptive potentials and therefore, have important
roles in the function of the mitoribosome.
Table 1. Distribution of GenBank variations within conservation bins
Conservation value
(Cv)
Number of sites
per category
Number of sites carrying
variations per category
Normalized number of sites
carrying variations per category
Number of variations
per category
Normalized number of
variations per category
2. CV ≥ 1.9 115 4 (3)a 9.72 333 (3)a 809.13 (7.29)a
1.9. Cv ≥ 1.5 150 31 57.25 158.00 291.77
1.5. Cv ≥ 1 239 67 77.65 4182.00 4846.92
1. Cv ≥ 0 277 73 73.00 3216.00 3216.00
Cv, 0 13 3 63.92 5.00 106.54
Not aligned 161 85 146.24 6666.00 11 468.83
Totals 955 263 427.78 14 560.00 20 739.20
Corrected values after subtraction of values corresponding to outlier residues shown in brackets. Normalization is to the bin with the highest number of sites carrying
variations (1 . Cv ≥ 0). In brackets are the values obtained for the most conserved bin (2 . Cv ≥ 1.9) after neglecting the 330 appearances of the outlier residue 180A
(m.827A).
aValues calculated for the 2. CV ≥ 1.9 category after neglecting the 330 appearances at position 827.
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For all the reasons evidenced above, a group of very rare
mt-12S rRNA variants were examined in this study. Specifically,
we have focused on 52 variations, including 46 mutations with
zero appearances in published controls and in the MITOMAP,
GenBank and Phylotree databases, plus the m.896A.G variant,
included due to their relevance to the presented results (Table 2
and Supplementary Material, Table S1). We have also analyzed
the following five variants: the ‘proven’ pathogenic mutations
847C.U (m.1494C.T) and 908A.G (m.1555A.G), included
as HIA positive controls (Table 2); the two common population
changes with an abundance over 5% of the GenBank population,
791A.G (m.1438A.G) and 62G.A (m.709G.A), included
as negativeHIA controls ( SupplementaryMaterial) and the afore-
mentioned, highly conserved outlier 180A.G (m.827A.G),
included to test whether a rationale to its strange behavior could
be discovered (Supplementary Material).
Conservation index (Ci) analysis
Many authors have relied heavily on very simple Cis for asses-
sing the potential pathogenicity of mt-rRNA mutations. We
have calculated three different types of Cis: two based on
primary structure conservation, CiUniv and Ci1ry; one based on
secondary structure conservation, Ci2ry; and a composite Ci
which combined the information obtained from the other three,
CiTot. The results are displayed in Table 2. A quick glance of
the table clearly shows the failure of Cis to predict pathogenicity.
For example, the two known pathogenic mutations 847C.U
(m.1494C.T) and 908A.G (m.1555A.G) display rather
low Cis. The implications of this are discussed below.
HIA analysis
The results of HIA analysis are shown in Table 2. Out of the 49
mutations analyzed (the negative controls and outlier were not
included in the table), we found 1 whose disruptive potential
on the function of mitoribosomes is ‘unlikely disruptive’, 18
which cannot be classified due to local structural differences
between the mitochondrial and the heterologous ribosomes (‘un-
determined’), 14 which are regarded as ‘not enough evidence
(NEE)’, 5 which are ‘likely disruptive’ and 9 which are ‘ex-
pectedly disruptive’ (see Materials and Methods). Finally, the
pathogenic mutations 847C.U (m.1494C.T) and 908A.G
(m.1555A.G) were classified within the ‘proven’ category.
Figure 2 shows the location of the mutations with the highest
disruptive potential, namely the ‘likely’ and ‘expectedly disrup-
tive’ categories, on the secondary-structure map of human
mt-12S rRNA. The location of the equivalent residues in
E. coli is shown in Figure 3. While the predictive power of phylo-
genetically derived secondary structure maps has been amply
confirmed experimentally by high-resolution structures of ribo-
somes from all three domains of life (24,27–29), we sought to
confirm the accuracy of our assignment of heterologous residues
by independently performing such an assignment in two SSU
rRNAs from distantly related organisms. This was followed by
their visualization in superposed high-resolution structures. To
this end, we used phylogenetically derived secondary-structure
maps and high-resolution crystal structures of SSUs from Tetra-
hymena thermophila (Eucarya) and E. coli (Eubacteria), both
organisms more distant phylogenetically than eubacteria and
mitochondria. The results of this comparison are displayed super-
posed onto the models of SSU rRNAs from these two organisms
(Fig. 4 and Supplementary Material, Movie S1). Our results
show a perfect structural match for all the studied mitochondrial
positions as long as structurally equivalent residues can be
located in phylogenetically derived, secondary structure maps of
the heterologous ribosomes. The structural agreement between
the predicted positions in both SSUs demonstrates that equiva-
lence at the secondary structure level translates into accurate
superposition in 3D. Thus, these data demonstrate the validity of
comparative analysis to accurately predict the location of such
structural equivalents in heterologous 3D ribosomal structures.
Structural placement of mitochondrial mutations in heterologous
ribosome structures provides the basis for HIA.
Below, we briefly describe the results of the HIA analysis for
the mutations arranged within the ‘likely’ and ‘expectedly dis-
ruptive’ categories.
Bridge B2c
Ribosomal bridge mt-B2c has the same chemical composition in
human mitochondria and in bacteria (30). Bridge b-B2c is
formed in E. coli by the packing of residues 770:771 of b-h24,
899:901 of b-h27 and 1512:1513 of b-h45, against the LSU resi-
dues 1831:1833 of b-H67 (Fig. 3) (29,31,32). The mutation
450G.A (m.1097G.A), which was identified in a COX-
deficient colonic crypt, maps to this region of 12S rRNA (33)
(Figs 2 and 3). The equivalent position in E. coli, G809, is base
paired to b-B2c residue C770 (Figs 3 and 5B). The evidence
for the possible involvement of the 450G (m.1097G) in the incor-
rect functioning of bridge mt-B2c appears quite likely, since the
disruption of the G809:C770 base pair by mutagenesis has been
shown to be detrimental to ribosomal function (34,35). In add-
ition, mutations disrupting Watson:Crick geometry at the adja-
cent G769:C810 base pair were highly deleterious (36,37). In
the specific case of the 450G.A (m.1097G.A) mutation, the
resulting C.A mismatch between 411C and 450G could adopt
wobble geometry and thus, impose a rather small structural dis-
tortion at the base of m-h24. Indeed, such a configuration has
been observed in 3.1% of mitochondrial SSU rRNAs (25).
Further evidence is necessary to establish whether such geom-
etry would be tolerated in this important region of the human
mitoribosome.
One more variation in the neighborhood of mt-B2c, an A.C
transition at position 507 (m.1154A.C), was identified in the
12S rRNA of a patient with hearing loss (38). TheE. coli equiva-
lent to this residue isA901, located in the highly conserved tetra-
loop that caps b-h27 (Fig. 5B). In the E. coli ribosome A901 is
involved in tertiary contacts with the ribose of residue 811C at
the base of b-h24, and with the backbone of residue A1513 in
b-h45 (39), underscoring its important role in the stabilization
of the complicated structure of the region. The importance of
base identity in the tetraloop, as well as that of the correct
packing of b-h27 and b-h24 for ribosomal function has been
demonstrated in mutagenesis studies (40). In particular, varia-
tions atA901 resulted in less than half of the normal ribosome ac-
tivity and moderate misreading effects (40).
In summary, the functioning of bridge mt-B2c could be com-
promised by two mutations found in human 12S rRNA,
450G.A (m.1097G.A) and 507A.C (m.1154A.C) (33,38).
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Table 2. Classification of mt-SSU rRNA mutations according to their predicted disruptive potential on ribosomal function
Disruptive power E. coli equivalent Conservation of position according to CRWa CiUniv Ci1ry Ci2ry CiTot
Unlikely
249A.G (m.896A.G) G524 g 3 4 5 19
Average NA NA NA 19
SD NA NA NA NA
Undetermined
67A.U (m.714A.T) G112 g 3 3 5 17
90C.U (m.737C.T) Unknown ? NI NI NI NI
103G.C(m.750G.C) Unknown ? NI NI NI NI
125A.G (m.772A.G) C271b x 0 2 2 6
167A.G(m.814A.G) G351 o 2 4 4 16
282A.U (m.929A.T) G557 x 0 0 3 3
296G.A (m.943G.A) G577 g 3 3 5 17
308A.G (m.955A.G) Unknown ? NI NI NI NI
313C.A(m.960C.A) Unknown ? NI NI NI NI
314U.A(m.961T.A) Unknown ? NI NI NI NI
314InsC(5)(m.961InsC(5)) Unknown ? NI NI NI NI
314delU(m.961delT) Unknown ? NI NI NI NI
361A.U (m.1008A.T) G711 w 1 2 4 10
364C.A(m.1011C.A) G714 g 3 2 4 14
474A.G (m.1121A.G) Unknown ? NI NI NI NI
485U.C (m.1132T.C) C879 w 1 4 4.5 14.5
878C.G(m.1525C.G) Unknown ? NI NI NI NI
888U.C(m.1535T.C) Unknown ? NI NI NI NI
Average 1.71 2.63 3.63 8.69 Average
SD 0.98 0.90 0.90 0.92 SD
NEE
40G.A(m.687G.A) G46 w 1 3 5 13
257C.U(m.904C.T) A532 o 2 4 5 17
265U.A(m.912T.A) G540 w 1 1 4 8
277A.U (m.924A.T) U552 w 1 1 4 8
620U.A (m.1267T.A) U1062 u 3 3 4.5 16.5
642G.C (m.1289G.C) U1083 o 2 2 5 13
698G.A (m.1345G.A) G1215 o 2 3 5 15
701G.A (m.1348G.A) G1218 w 1 2 5 11
727A.G (m.1374A.G) C1245 w 1 1 2.5 6.5
733G.A (m.1380G.A) G1294 w 1 1 4.5 8.5
742G.A (m.1389G.A) G1304 g 3 2 5 15
897A.U (m.1544A.T) C1479 x 0 3 4 10
929G.A (m.1576G.A) G1511 o 2 4 5 17
939G.A(m.1586G.A) C1521 w 1 4 5 15
Average 1.38 1.79 4.34 11.13 Average
SD 0.78 1.19 0.74 3.83 SD
Likely
450G.A (m.1097G.A) G809 o 2 4 5 17
507A.C (m.1154A.C) A901 a 3 3 5 17
676G.A (m.1323G.A) G1193 o 2 4 4.5 16.5
680G.A (m.1327G.A) A1197 w 1 3 5 13
852U.C (m.1499T.C) G1415 w 1 1 4.5 8.5
Average 1.50 2.31 4.79 13.41 Average
SD 0.84 1.22 0.27 3.70 SD
Expectedly
232U.C(m.879T.C) C507 c 3 3 5 17
255G.A (m.902G.A) G530 G 4 5 5 23
522G.A (m.1169G.A) U916 o 2 5 5 19
533U.G (m.T1180T.G) G927 w 1 4 5 15
579C.G (m.1226C.G) C972 C 4 5 5 23
580G.A (m.1227G.A) G973 g 3 4 5 19
910A.C (m.A1557A.C) A1492 A 4 4 4 20
915G.A (m.1562G.A) G1497 G 4 6 5 25
919C.U (m.1566C.T) C1501 c 3 5 5 21
Average 2.57 4.39 4.86 19.77 Average
SD 1.05 0.88 0.33 3.15 SD
Continued
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Mutagenesis studies performed in bacteria around the heterol-
ogous equivalent of 450G (m.1097G) indicated an important
role of this region in ribosomal function. However, it is still pos-
sible that the helical geometry introduced by the G.A mutation
in the organellar ribosome could be accommodated without a
major deleterious effect. As for 507A.C (m.1154A.C), the pa-
ternal inheritance of the deafnesspattern rules out a primary causa-
tive effect for the mutation (38). However, the disruptive potential
of the base change is quite high, in agreement with the possibility
that 507A.C (m.1154A.C) might contribute to the hearing
defect. As a result, we are prompted to assign both mutations to
the ‘likely disruptive’ category.
Central pseudoknot
A G to A mutation at position 522 (m.1169G.A) in the central
pseudoknot of the SSU has been found in a patient with renal car-
cinoma (41). Figure 5C shows positionU916, theE. coli equiva-
lent to 522G (m.1169G) that is base paired to residueA19within
the central pseudoknot (Figs 3 and 5C). This universally con-
served structure, whose formation is believed to constitute a
crucial step during the maturation of the SSU (42), has been thor-
oughly studied by mutagenesis in bacteria. The results were
clear. Essentially, base complementarity and not primary se-
quence were required to maintain ribosomal function (43–45).
Thus, it appears reasonable to assume that the 522G.A
(m.1169G.A) mutation should result in a defective SSU and
so we have assigned this mutation to the ‘expectedly disruptive’
category.
The 530 loop
The 530 loop is one of the most important functional centers of
the ribosome and, as such, its primary sequence is highly con-
served phylogenetically across all three kingdoms of life
(Figure 5). A homoplasmic G to A mutation was identified at pos-
ition 255 (m.902) in a COX-deficient sample of urothelial cell
patches (46). The bacterial equivalent is key residue G530
from which the loop receives its name. G530 has been shown
to participate in monitoring the fidelity of decoding by checking
the codon-anti-codon interaction at the A site (Fig. 5D and G)
(47,48). Since alterations at G530 have been shown to result in
dominant lethal phenotypes (49), we must include the 255G.A
(m.902G.A) mutation in the ‘expectedly disruptive’ category.
Two more mutations map to this important structural element
of the human mitoribosome. The extremely rare variation
232U . C (m.879T . C) was identified in a COX-deficient
colonic crypt and in a cancer patient (33,50). The equivalent pos-
ition inE. coli, 507C is base paired to 524Gwithin a pseudoknot
motif that provides structural stability to the 530 loop (Figs 2 and
3) (51). While the primary sequence of the pseudoknot is highly
conserved, the identity of the bases constituting the507:524base
pair is different in bacteria and human mitochondria. The bacter-
ial pseudoknot was originally dissected by site-directed muta-
genesis (51). It was shown that single base changes on either
side of this structural element resulted in severe growth defects
that could be restored by second-site, compensatory mutations
(51). Interestingly, an A.G base change at the human equivalent
of G524, namely 249A (m.896A) appears in 20 GenBank
sequences and in a MITOMAP unpublished sequence (http://
mitomap.org/bin/view.pl/MITOMAP/Submissions/20100804015).
These observations suggest that certain mutationswithin the pseu-
doknotstructureare tolerated in the organellar ribosome.Abenign
phenotype for 249A.G (m.896A.G) would not be in disagree-
ment with HIA data and could be explained structurally. This is
because G:U/U:G base-pair schemes within the pseudoknot are
well tolerated in bacteria, including the very same scheme that
would be induced by the 249A.G (m.896A.G) mutation
(51,52).
The disruption of the bacterial pseudoknot, involving residues
507 and 524, likely impairs the function of the G530 in A-site de-
coding(47,48). Inaddition,disruptionof thepseudoknotcouldalso
affect the maturation of SSU rRNA, as shown inE.coli (53).Taken
together, these data allow the assignment of 232U.C (m.879T.
C) within the ‘expectedly disruptive’ category, whereas 249A.G
(m.896A.G) must be considered an ‘unlikely disruptive’ poly-
morphism.
Helix 28
The 533U.G (m.1180T.G) mutation was identified in one
pediatric subject with non-syndromic hearing loss (54). The
E. coli equivalent is G927 that is base paired to U1390 in helix
h28 (Figs 2 and 3). Next to this site is the universally conserved
G926 (conservation between 98 and 100%) (25), which is
Table 2. Continued
Disruptive power E. coli equivalent Conservation of position according to CRWa CiUniv Ci1ry Ci2ry CiTot
Proven
847C.U (m.1494C.T) A1410 w 1 4 4 14
908A.G (m.1555A.G) U1490 w 1 3 4 12
Average 1.89 2.99 1.89 11.90 Average
SD 1.31 1.45 1.50 6.71 SD
NI, no information; NA, not applicable. The table includes all mitochondrial mutations meeting the criteria described in the section Materials and Methods. Only the
mutations within the ‘likely’ and ‘expectedly’ categories have been analyzed in detail in this paper. Cis were calculated as described in the section Materials and
Methods. Whenever possible, Cis were averaged in a per-category fashion and a standard deviation was calculated.
aCannone et al. (25) nomenclature for primary standard conservation across all three phylogenetic kingdoms is included. A, C, G, U, N, nucleotide is conserved in 98–
100% of the sequences in the alignment; a, c, g, u, n, nucleotides is conserved in 90–100% of the sequences in the alignment; o, nucleotide is conserved in 80–90% of
the sequences in the alignment; w, nucleotide is conserved in ,80% of the sequences in the alignment; x, position is conserved in ,95% of the sequences in the
alignment.
bTentative assignment.
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Figure2.Secondary structure map of the human 12S mt-rRNA showingsites of mutation. The secondary-structure map of human mt-12S rRNA was obtained from the
CRW site (25). Sites of mutation analyzed in the main text are shown in black font. Other important sites described in the text (including HIA positive controls) are
shown in white font over the black background. HIA negative controls are shown in black font over the gray background.
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Figure 3. Bacterial equivalents of mitochondrial mutations. Bacterial equivalents of analyzed mutations are shown in black font on the secondary-structure map of
E. coli 16S rRNA (25). Other important sites described in the text (including HIA positive controls) are shown in white font over the black background. HIA negative
controls are shown in black font over the gray background.
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hydrogen bonded to the phosphate linking the P- and E-site
codons on the mRNA (55) (Fig. 5E). In agreement with the im-
portant role of this region in translation, mutagenesis studies per-
formed in yeast have shown that several base changes at the
equivalent positions to 926, 927 or 928 confer lethal phenotypes
(56). Similarly, functional studies in bacteria demonstrated that
all three mutations at G926 drastically reduce the activity of the
mutant ribosomes (57), albeit with only moderate effects on cell
growth (58). Finally, b-h28 has been recently proposed to serve
as the spring of the ratcheting process undergone by the ribosome
during translocation (31). In summary, the available evidence
obtained from different model organisms, points to an important
involvement of h-28 residues in ribosomal function. As a result,
the 533U.G (m.1180T . G) transversion is a good candidate
for an ‘expectedly disruptive’ mutation.
Helix 31
A C to G transversion has been identified at residue 579C
(m.1226C) in a pediatric subject with non-syndromic hearing
loss (54). Interestingly, a G.A transition at the adjacent 580G
(m.1227G) was reported to be associated with schizophrenia in
a single patient by Ueno et al. (59). While the 580G.A
(m.1227G.A) mutation was properly placed on a phylogenetic-
ally derived, secondary-structure map of the mammalian mt-12S
rRNA by the authors (59), no further inquiries regarding the
structural and/or functional role of the residue were pursued.
The E. coli equivalents to 579C (m.1226C) and 580G
(m.1227G) are the universally conserved residue C972 and the
highly conserved G973 (Figs 2 and 3). These residues map to
the vicinity of the P- and A-site anticodon stem loops (ASLs)
in the decoding site (Fig. 5F). Residue C972 is base paired to
G963, which is also universally conserved and places one of
its phosphate oxygens ,5 A˚ away from the backbone of the
A-site ASL (Fig. 5F) (25,60). This base pair and the one
formed by G973 and C962 appear to be important for the stabil-
ization of the complicated structure of the loop atop helix b-h31
(Fig. 5F). Not surprisingly, mutations in this region have been
found to disrupt ribosome activity in E. coli. For example, base
changes atC972,G963 andA964 produced moderately deleteri-
ous, but dominant growth defects, whereas mutations at G973
strongly impaired cell growth (61). Finally, the physical proxim-
ity of the C972:G963 to the A-site ASL explains the observed
effects of mutations in the region on the fidelity of A-site decod-
ing (62). In summary, both the 579C. G (m.1226C . G) and
the 580G.A (m.1227G.A) mutations are expected to be
highly disruptive to the function of the mitoribosome.
Helix 34
The mutations 620U.A (m.1267T.A) (63) and 676G.A
(m.1323G.A) (64), mapping to mt-h34, have been identified
in three cancer patients (see Supplementary Material, Table
S1). This area of the ribosome has been implicated in the move-
ment of the SSU head during translocation and in the binding of
the translocation inhibitor spectinomycin (31,65,66). Indeed, the
residue equivalent to 620U.A (m.1267T.A) in the chloro-
plasts of Nicotiana tabacum and of Chlamydomonas is a spec-
tinomycin resistance (specR) site (65). In E. coli, the
equivalent residues to 620U.A (m.1267T . A) and
676G.A (m.1323G.A) are 1062U and 1193G, which base
pair to U1194 and C1063, respectively. Adjacent to the
C1063:G1193 base pair are residues G1064 and C1192
(Fig. 5G), which are part of the binding site for the antibiotic
spectinomycin (55,66), an antibiotic proposed to restrict head
movement by increasing the rigidity of the region around these
residues (55,66). Despite their identity and location on the sec-
ondary structure map, G1064 and C1192 do not form a
Watson–Crick base pair in the bacterial ribosome. Indeed, the
human mt-SSU rRNA contains a U.C mismatch at the positions
Figure 4. Placement of heterologous equivalents of mitochondrial mutations on the high-resolution structures of T. thermophila and E. coli. (A) Ball representation
of superposed heterologous residues.T. thermophila, grey;E. coli, black.E. colinumbering indicated. (B) Same residues onto ribbon models of theT. thermophila and
E. coli SSUs. RCSB accession codes 2I2P and 2XZM.
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equivalent to G1064 and C1192 (compare Figs 2 and 3). Muta-
genesis analysis of G1064 and C1192 has shown that mutations
at both sites are well tolerated and confer resistance to spectino-
mycin (66,67). In contrast, mutations at G1193, also conferring
spectinomycin resistance inE. coli, do so with a clear fitness cost
(68). While no mutagenesis data exist for eitherU1062or its non-
canonical base -pairing partnerU1194, it is striking that the iden-
tity of both residues, forming a U.U mismatch, is conserved in
human mitochondria. Analysis of the quaternary structure of
the region shows that the N-terminal region of protein b-S3
makes direct contacts with the base of U1062 and with the
RNA backbone at C1192 (Fig. 5G). The significance of this
observation cannot be extrapolated to the organellar case,
however, as a protein homologous to b-S3 is not present in the
mitoribosome.
In summary, while some mutations in this region can be well
tolerated in bacteria, others result in deleterious phenotypes.
Specifically, the heterologous evidence appears quite solid for
a potentially disruptive role of 676G.A (m.1323G.A). On
the other hand, a prediction of the disruptive potential of
620U.A (m.1267T.A) cannot be based solely on the available
heterologous data.
Another mt-h34 mutation, namely 680G.A (m.1327G.A),
has been identified as homoplasmic in atrophic prostate epithe-
lium (69). Its bacterial equivalent is position 1197, which in
Thermus thermophilus is also a G (A inE. coli). While mutagen-
esis studies at position 1197 have not been carried out, the fol-
lowing information provides evidence for an important role in
translation. First, position A1196 of E. coli has been cross
linked to residues +5, +8 and +9 of the mRNA and shown to
be protected by the binding of elongation factor G (70–72).
Indeed, position 1196 is modeled in close proximity of the
A-site codon–anticodon interaction in high-resolution struc-
tures of the bacterial ribosome (Fig. 5) (60). All these data
taken together prompt us to consider 680G.A (m.1327G.A)
as a ‘likely disruptive’ mutation.
Figure 5. Placement of mitochondrial mutations in the structures of bacterial SSUs. (A) Surface representation of theE. coli SSU showing the location of the residues
shown in B–I. (B) 530 pseudoknot. RCSB accession code 2J00. (C) Central pseudoknot. RCSB accession code 2I2P. (D) Bridge b-B2c. RCSB accession codes 2I2P
and 2I2T. (E) 927 region. RCSB accession code 2J02. (F) 972 region. RCSB accession code 2J02. (G) Mutations in b-h34 and A-site codon–anticodon interaction.
RCSB accession code 2J00. (H) b-h44. The aminoglycoside antibiotic paromomycin is shown in orange. RCSB accession code 2J00. (I) Decoding region of b-h44.
RCSB accession code 2J00. (B–I) Bacterial equivalents of mitochondrial mutations shown in yellow. Other residues mentioned in the main text are shown in gray. 16S
rRNA shown in gray. P-site ASL in red, A-site ASL in purple, mRNA in green, ribosomal proteins in black and 23S rRNA in blue. Inter-atomic distances are indicated,
but note that ribbon representations do not necessarily reflect accurate interatomic distances involving backbone atoms.
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Helix 44
A U to C transition at position 852 (m.1499T.C) has been iden-
tified in a breast cancer patient (73). The equivalent position in
E. coli would be G1415 within b-h44 (Figs 2 and 3). G1415 is
base paired to U1485, which is part of inter-subunit bridge
b-B3, a structure that appears to be conserved in the mitoribosome
(Fig. 5H) (30,32). We have recently targeted the adjacent position
C1484ofE. coliSSU’s rRNAfor site-directed mutagenesis tofind
that alterations of the helical stability of this region can cause
highly deleterious phenotypes (74). Similarly, mutations of the
b-B3 partner region on the bacterial LSU also resulted in defective
ribosomes (75), in agreement with the finding that bridge b-B3 is
the pivot point for inter-subunit ratcheting (31).Thus, all the avail-
able evidence points at an important role of residue 852U
(m.1499T) in the mitoribosome and argue for a likely disruptive
role for the U to C transition at this position.
A highly interesting variation was recently listed in the
MITOMAP unpublished variant database. The variation
910A.C (m.1557A.C) was identified in a Russian individual
suffering from deafness (http://www.mitomap.org/bin/view.pl/
MITOMAP/Submissions/20070709002). Its bacterial equiva-
lent, the universally conserved A1492 is, together with A1493,
one of the most important residues of the ribosome. The func-
tional role of these adenosines is to monitor the geometry of
the codon–anticodon interaction at the A-site (Fig. 5H and I)
(47,48). In bacteria, mutations at A1492 or A1493 result in dom-
inant lethal phenotypes (57,76,77). Clearly, 910A.C
(m.1557A.C) constitutes an extremely well-qualified candi-
date for a highly disruptive mutation.
The 915G.A (m.1562G.A) mutation was identified in a
COX-deficient colonocyte in a study investigating clonally
expanded mtDNA mutations associated with aging (78). The
bacterial equivalent to this residue is the universally conserved
G1497, adjacent to the P-site codon on the mRNA and is base
paired to the also universally conserved C1404 (Fig. 5H and I).
The phosphate between G1497 and U1498 is within h-bonding
distance of the 2′OH of position +1 of the mRNA, i.e. the first
base of the P-site codon (60). Not surprisingly, mutagenesis
studies showed that disrupting the C1404:G1497 base pair
resulted in serious impairment of tRNA binding at both P and
A sites (79). Due to all these observations regarding the bacterial
equivalent of 915G.A (m.1562G.A), the organellar mutation
is clearly expected to result in a deleterious mitochondrial
phenotype.
A 919C.U (m.1566C.T) transition has been identified in a
cancer patient (41). The bacterial equivalent is the highly con-
served 1501C, which is base paired to 1401G in the vicinity of
the codon–anticodon interaction at the P site (Figs 2, 3 and
5I). Indeed, the adjacent 1400C is stacked under position 34 of
P-site tRNA (55). In agreement with their location, mutagenesis
studies have shown that altering the 1401G:1501C base pair
completely abolishes ribosomal function (80,81). Hence, the
heterologous evidence clearly places this mutation in the ‘ex-
pectedly disruptive’ category.
DISCUSSION
Currently, all available structural information pertaining to the
mammalian mitoribosome is contained within phylogenetically
derived secondary structure maps of its rRNA components and in
a single low-resolution reconstruction of the bovine organellar
ribosome (25,82). Here, we have made the first systematic dem-
onstration that this information can be combined with data
obtained from heterologous sources to make predictions on the
disruptive potential of mt-rRNA mutations. We believe that
this exercise constitutes a valid first approximation toward
understanding the role of these mutations in human disease.
Indeed, we propose that these methods should become one of
the prime functional tests for the examination of novel or rare
mt-rRNA variants seen in the mtDNA of patients.
The predictive power of comparative analysis for the gener-
ation of structural predictions on the folding of large RNAs
has been confirmed by the high-resolution structures of the ribo-
some (24,28). For this reason, it has been surprising to find that,
except for one report (59), no attempt has been made to use
phylogenetically derived secondary-structure maps for the inter-
pretation of the available mutational data. This has, in some
cases, resulted in quite inaccurate structural predictions that
remain uncontested in the literature. For example, Mutai et al.
(83) have used the program CENTROIDFOLD (84) to predict
the disruptive potential of the 257C.U (m.904C.T) mutation.
According to the authors, the C–U base change would disrupt
the canonical G–C base pair between 242G and 257C (83).
However, such a canonical base pair is not predicted by
phylogenetic methods (Fig. 2) and is not substantiated by high-
resolution data from heterologous sources, as shown in Supple-
mentary Material, Figure S4.
HIA and Ci analysis
In addition to HIA, we have also attempted to assign a Ci to all
mutations, as described in the section Materials and Methods.
This has been a common practice among researchers attempting
to make sense of mutational data pertaining to mt-rRNAs. One
of the main novelties of our Ci analysis is to include primary
and secondary structure information from the region surrounding
the tested residue (Ci1ry andCi2ry), asopposed tomost reportedCis
that merely reflect the conservationof said residue (54,83,85–87).
Regarding conservation, we have measured this parameter across
the width of phylogenetic tree (CiUniv). In contrast, most authors
have restricted their conservation analysis to a narrow range of
phylogenetic space (54,83,85–87). While this practice works
for other mitochondrial genes, we believe that the potential im-
portance of the high number of exceptionally well-conserved resi-
dues of rRNA would be underestimated by Cis based on a narrow
proportion of the total rRNA variation found on the tree of life.
While our results show that Cis have some potential to predict
the assignment of an important subset of mutations according to
their HIA-predicted disruptive power, especially those within
the‘expectedly’category,Ciscannotberelieduponfor the assign-
ment of pathogenicity to most mutations. One striking example is
that of the ‘unlikely disruptive’ 249A.G (m.896A.G) muta-
tion, for whichall fourCis arewellover theaverage valueobtained
for the ‘expectedly disruptive’ category. Similarly, some muta-
tions within the ‘undetermined’ category display Ci scores that
would place them within the ‘likely’ or even the ‘expectedly’ cat-
egory, e.g. 67A.U(m.714A.T), 167A.G(m.814A.G) and
296G.A (m.943G.A). However, the best proof of the very
limited predictive power of Cis in the context of mt-rRNA
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mutations is obtained when the ‘proven’ pathogenic mutations
847C.U (m.1494C.T) and 908A.G (m.1555A.G) are
taken into account. The low Cis assigned to these mutations
clearly demonstrate the limitations regarding their use as a way
to obtain insightful information on the pathogenicity of
mt-rRNA mutations.
In the case of universally conserved residues, both CiUniv and
HIA predictions agree. It should be noted, however, that harmless
or mildmutations at universally conservedrRNAresidues do exist
(58). As a result, the agreement between CiUniv and HIA predic-
tions would be lost for such mutations. In summary, while the pre-
dictive potential of Cis remains an open issue, it appears clear that
Ci analysis should always be applied in conjunction with HIA.
This leads to a situation similar to that found while reporting
mt-tRNA variants (6,7,10). Accordingly, a reliable assessment
of pathogenicity of an mt-rRNA variant might require collabora-
tive efforts between research centers to bring together the required
analytical skills (9,88).
Disruptive power and pathogenicity
How much damage to ribosomal function is necessary for patho-
genicity, and how do other factors modulate the amount of
damage caused by mt-rRNA variants? Here we make the assump-
tion that ribosome disruption leads to defective organellar protein
synthesis, which translates into mitochondrial dysfunction, and
finally into clinical symptoms. This highly simplistic assumption,
substantiated by an enormous amount of evidence both from the
point of view of the ribosome and that of the mitochondrion, will
serve as a first approximation toward the analysis of the pathogenic
potential of mt-rRNA mutations. The only two mt-rRNA muta-
tions whose pathogenicity has been established with certainty
are 908A.G (m.1555A.G) and 847C.U (m.1494C.T). The
bacterial equivalents of these residues, namely positions 1490
and1410, arepartof thebindingsite foraminoglycosideantibiotics
(Fig. 5H) (55). Despite their clear pathogenicity, when 908A.G
(m.1555A.G) and 847C.U (m.1494C.T) mutations were
recreated in bacterial systems, the cell growth was not completely
arrested and the translation rate was not markedly decreased (89).
Instead, a clear reduction in accuracy was observed in these studies
(89). These results indicate that pathogenicity of mt-rRNA muta-
tions can be achieved with ribosomes that can fully support trans-
lation, albeit with decreased accuracy. The fact that external
modifiers, such as aminoglycoside antibiotics or nuclear
markers, are needed to achieve the full pathogenic potential of
908A.G (m.1555A.G) and 847C.U (m.1494C.T) (21,90),
suggests that, much like in the bacterial case, the mitochondrial
mutations also result in functional ribosomes.
One would expect that mutations resulting in translation defects
moresevere than thoseconferredby908A.G(m.1555A.G)and
847C.U (m.1494C.T) will not need the presence of additional
factors to result in mitochondrial failure. Some examples of muta-
tions expected to result in complete disruption of ribosomal func-
tion are contained within the ‘expectedly disruptive’ category. In
principle, it seems reasonable to assume that ribosomes carrying
severely disruptive mutations could co-exist in heteroplasmy
with their wild-type counterparts. A similar co-existence of wild-
type and mutant ribosomes has been frequently recreated in bac-
teria, where the dominance/recessiveness of highly deleterious
mutations can be easily modulated by shifting the level of the
mutant particles (91). The maintenance of bacterial growth is
then dependent on the existence of enough wild-type ribosomes
to support a sufficient level of protein synthesis. Extrapolating
from the bacterial case, the heteroplasmy threshold above which
the levels of disruptive mt-rRNAmutations would becomeincom-
patible with normal mitochondrial function would be expected to
depend on two main factors. First, the severity of the deleterious
effect caused by the base changes on the function of the mutated
ribosomal particles (61,91,92). Secondly, the presence of pheno-
typic modifiers either in cis or in trans with the rRNA mutation.
In the absence of direct biochemical data, a recent study in
which the load of the 908A.G (m.1555A.G) mutation in a
Chinese family was monitored becomes highly illustrative. The
study showed that higher levels of heteroplasmy consistently
resulted in more severe symptoms (93), thus mirroring the bacter-
ial situation. In this study, heteroplasmy levels,20% were found
in asymptomatic individuals, levels 50% in slightly affected
individuals and .70% in severely affected patients (93).
Based on the large body of direct structural, mutational and
functional data gathered in heterologous ribosomes, the mutations
with the highest disruptive power described in this paper are
255G.A (m.902G.A) and 910A.C (m.1557A.C) (46)
(http://www.mitomap.org/bin/view.pl/MITOMAP/Submissions/
20070709002) which, in mitochondria, affect the key A-site resi-
dues in the mitochondria, equivalent to the bacterial G530 and
1492A, respectively (49,57,76). These nucleotides are amongst
the most important ribosomal residues from the functional point
of view and, therefore, it comes as no surprise that mutations at
both G530 and 1492A have been found to cause dominant lethal
phenotypes in bacteria (49,57,76). While in the case of the mito-
chondrial equivalent to 1492A, namely 910A.C (m.1557A.C)
(http://www.mitomap.org/bin/view.pl/MITOMAP/Submissions/
20070709002), we lack data regarding heteroplasmy levels, the
bacterial data strongly suggest that this mutation can only be
present at low levels if the mitochondria are to retain their function
(49,77).However, what constitutes the actual threshold for a defect
caused by this mutation is currently unknown. As for the homo-
plasmic 255G.A (m.902G. A) (46), the fact that the all point
mutations at its bacterial equivalent resulted in dominant lethal
phenotypes, together with the central role of this residue in decod-
ing, is a strong indication that all ribosomes in the mutant mito-
chondria are incapable of performing protein synthesis. As a
result, this mutation meets all pathogenicity criteria proposed for
a homoplasmic mutation: absence from healthy controls, re-
markable phylogenetic conservation and unequivocal evidence
of a functional defect of the mutant ribosome (9). While the evi-
dence for a functional defect has been obtained in heterologous
systems, the available data are so strong that pathogenicity can
hardly be contested.
Two more ‘expectedly disruptive mutations’ 533U.G
(m.1180T.G) and 579C.G (m.1226C.G) have also been
found in homoplasmy (54). The disruption of the yeast equivalent
to the mitochondrial U533:G827, formed between positions 927
and 1390 (bacterial numbering), gave rise to recessive lethal phe-
notypes. While such phenotypes are not as drastic as the dominant
lethality caused by mutations at the bacterial G530 and A1492, the
presence of 533U.G (m.1180T.G) in homoplasmy indicates
that the affected mitochondria should be highly impaired in
their ability to carry out protein synthesis, thus leading to mito-
chondrial dysfunction. The case of 579C.G (m.1226C.G) is
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different. Despite the fact that the CiTot for thisposition is the same
as that of 255G.A (m.902G.A) and higher than that of
910A.C (m.A1557A.C), it has been shown that disrupting
the heterologous equivalent of the mitochondrial 570G:579C
base pair, namely b-963G:972C, results in moderate dominant
defects. Thus, the 579C.G (m.1226C.G) mutation is expected
to result in at least suboptimal protein synthesis. Whether this can
lead to enough organelle dysfunction to cause clinical phenotype
remains unclear. The case of 579C.G (m.1226C.G) constitutes
yet another example of the fact that Cis cannot be used to predict
the disruptive potential of rRNA mutations even in the heterol-
ogous systems used as references in these studies. At the same
time, this mutation underscores the enhanced discriminatory
power gained by using HIA.
In summary, whilst a clear case for pathogenicity can be made
for the 255G.A (m.902G.A) and the 533U.G (m.1180T.G)
mutations, the 579C.G (m.1226C.G) mutation cannot be con-
sidered pathogenic by HIA alone.
Role of HIAwithin a scoring system formt-rRNAmutations
The existence of direct experimental data showing a mitochon-
drial defect caused by a mtDNA mutation is an essential
pre-requisite of the current scoring systems to evaluate the patho-
genicity of mt-tRNA and complex I genemutations (6,7,9–11). In
the absence of direct biochemical data, HIA provides an educated
estimation of the disruptive potential of an important subset of
mt-rRNA mutations. This situation is reminiscent of the pre-
crystallography days (1990s) in which the study of ribosome
structure had to rely on evidence obtained from low-resolution
studies.Notably, the qualityof HIA predictions canbesubstantial-
ly improved as additional heterologous data emerge. As such, this
research provides new impetus for studies aimed at testing the
effect of equivalent mutations in heterologous systems and consti-
tutes an invitation to ‘ribosomologists’ to contribute to the im-
provement of HIA predictions, thus leading to higher diagnostic
accuracy in mitochondrial clinics. An obvious first aim of such
a collaborative effort between clinical and basic science should
be to move as many of the ‘NEE’ mutations to the ‘likely disrup-
tive’ or, perhaps, to the ‘expectedly disruptive’ category, by
means of site-directed mutagenesis and biochemical studies in
heterologous systems.
The importance of mutagenesis studies in heterologous systems
as a way to ascertain the effects of mt-rRNA alteration studies is
best exemplified by the case of the 908A.G (m.1555A.G) and
847C.U (m.1494C.T) mutations. When the mutations were
introduced in bacteria, the observed phenotypes were in perfect
agreement with the mitochondrial data (89,94). This, together
with structural evidence (95), provided a molecular explanation
to the pathological symptoms related to the mitochondrial muta-
tions, namely that misreading of the genetic code in mitochondria
can lead toadefectiveorganelle (89).Therefore,HIAwouldclearly
result in an ‘expectedly disruptive’ score for these mutations.
We have also shown that in cases where sufficient information
exists regarding the genetic and pathological manifestation of
the mutation, HIA alone can be used to predict the pathogenicity
of certain mt-rRNA mutations. In these cases, the heterologous
data are strong enough to replace direct biochemical evidence.
In other cases, the disruptive potential predictions will be incor-
porated into a full-fledged scoring system for mt-rRNA that will
allow an evaluation of their pathogenic potential. In addition to
the usual elements, the mt-rRNA scoring system will include
HIA predictions and CI scores. As mentioned above, the level
of heteroplasmy, together with the degree of disruption of ribo-
somal function, will constitute major elements of the scoring
system. Here again, future HIA-motivated studies performed
in heterologous systems can provide extremely useful informa-
tion. For example, quantitative studies with hybrid populations
of ribosomes in bacteria (91) could be used to assess the hetero-
plasmy threshold at which mt-rRNA mutations become detri-
mental to normal protein synthesis.
Final conclusions
Here, we have presented what we believe will be a central element
of a scoring system for mt-rRNA mutations. HIA analysis appears
to be a powerful tool that could help overcome the lack of bio-
chemical and/or trans-mitochondrial cybrid data, which are con-
sidered to be crucial elements of the scoring systems for mt-tRNA
and complex I genes (6,7,10,11). It should be noted that a simple
‘no-appearance-in-controls’ requisite, as established ever since
the canonical criteria of DiMauro and Schon were established,
will result in the discarding of well-known pathogenic mutations
such as 908A.G (m.1555A.G) and 847C.U (m.1494C.T),
underscoring the variability in penetrance of this group of muta-
tions. One important challenge for the future must be to account
for any effect of haplogroup background, as there is increasing
evidence that this parameter is important in both the presentation
and penetrance of mtDNA disease (22). Future analysis of
mt-rRNA mutations will require that authors report their data
fully including all the variants from the rCRS (particularly var-
iants mapping to rRNA and tRNA genes), haplogroup definition,
heteroplasmy levels, patient/control group sizes and data on the
family/cohort structure. Similarly, mitochondrial genome
sequences submitted to GenBank should clearly state whether
the subject is considered a patient or a control.
While HIA predictions alone would not be sufficient for a de-
finitive assignment of pathogenicity, except for some key resi-
dues with critical functional roles such as 255G.A
(m.902G.A) and 533U.G (m.1180T.G), the method does
provide a robust indicator of disruptiveness for a large group
of mutations lacking direct evidence regarding their role in mito-
chondrial dysfunction. At the same time, HIA naturally allows
the prioritization of variants for additional investigation.
MATERIALS ANDMETHODS
Nomenclature
Since the focus of this paper is the mitoribosome, all mt-rRNA
base changes will be referred to by their gene, rather than their
genomic position. For clarity, however, the genomic position
will also be provided in brackets. Bacterial rRNA residues
will be italicized throughout the text. Mitochondrial specific no-
tation will be used to denote organellar base changes, e.g.
m.1111A.G. Likewise, bacterial nomenclature will be used
to denote bacterial base changes, i.e. A1111G. To distinguish
structural elements in the bacterial and mitochondrial ribosomes
their name will be preceded by b- and mt-, respectively. Small
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subunit helices are denoted by ‘h’ and large subunit helices are
denoted by ‘H’.
Sources of mutational data
The following sources of mutational data were used in this study:
(a) scientific literature, (b) MITOMAP list of unpublished var-
iants (1), (c) GenBank, (d) Phylotree (96) and (e) three unpub-
lished variations (see below).
The criterion required for mt-rRNA mutations to be included
in this study was their identification in human subjects, with
either a suspected mitochondrial disease or somatic mtDNA
mutations that had undergone clonal expansions in cancer
patients, or COX-deficient cells located in aged tissues (97). In
the case of studies involving tumorigenic tissue, the existence
of non-cancerous control tissue from the same patient was a re-
quirement. Similarly, the existence of COX-proficient surround-
ing tissue was a requirement in the case of COX-deficient
samples of aged individuals. This allowed the variant to be iden-
tified as a somatic mutation that had undergone clonal expansion.
mtDNA sequencing
Mutation 878C.G (m.1525C.G) was detected as follows.
Total DNA was extracted from patient tissues using standard
DNA extraction methodologies. The entire mitochondrial
genome was amplified using 36 overlapping primer pairs as pre-
viously described (33). PCR products were cycle sequenced
using ABI BigDye chemistry by following standard manufac-
turer’s protocols and analyzed on an ABI3130xl genetic analyzer
(Applied Biosystems). Mutations 125A.G (m.772A.G) and
361A.U (m.1008A.T) were identified as follows. The entire
mtDNA of the patients was evaluated using a standard mitochip
analysis (GeneChipw Human Mitochondrial Resequencing
Array 2.0, Affymetrix, Inc.). Percentage heteroplasmy was
quantified using the Pyrosequencing technology (Biotage AB,
Uppsala, Sweden) on the PSQ96 MA platform according to
the protocol of the manufacturer.
Analysis of GenBank mitochondrial genome data
As of February 2013, there existed 17 850 human mtDNA
sequences in GenBank [query¼ ‘Homo[Organism] + AND +
gene_in_mitochondrion[PROP] + AND + 14 000:19000[SLEN]
+ NOT + pseudogene[All Fields]’ (98)]. All sequences were
downloaded with Entrez Programming Utilities and our own
PERL scripts (99). In addition, we also downloaded 210 sequences
from http://www.phylotree.org/ that were not included in the
GenBank collection as of May 2012. The data were downloaded
in FASTA format and sequentially aligned to the Cambridge Ref-
erence (NC_012920.1) (100) by means of the MAFFT package
(101), which provided a quick algorithm for massive sequence
alignment. The generated alignments were then analyzed by
means of a PERL script that recorded the total number of appear-
ances for every variation. For variations with 15 or less appear-
ances in the combined data set, including the data from both the
GenBank and Phylotree databases, the possibility that the individ-
ual sequences could be linked to mitochondrial disease was inves-
tigated, by inspecting the related publication sources. Inall cases, it
was observed that no new patient sequences, other than the ones
previously found in the literature, were present within GenBank.
Assignment of the disruptive power potential by HIA
Phylogenetically derived, secondary-structure rRNA maps
carry an enormous amount of conservation information that
can be used to infer the relative positions of equivalent residues
from organisms located at opposite ends of the universal phylo-
genetic tree. HIA uses this information as follows. First, com-
parison of phylogenetically derived secondary structures of the
human mt-12S rRNA and the E. coli 16S rRNA (normally
used as the standard numbering system for rRNA residues)
(25) allowed the location of structurally equivalent residues.
Secondly, once the position of a structurally equivalent residue
was identified, its location in three dimensions (3D) was ascer-
tained by visualization in high-resolution models of heterol-
ogous ribosomes (normally atomic models of the E. coli or
T. thermophilus ribosomes). Subsequent analysis of the region
surrounding the heterologous residue within the high-resolution
structures provided a first approximation of the structural role of
the mutated mitochondrial residue. Thirdly, an exhaustive
search for additional structural and functional information
regarding the heterologous residues was performed. Finally,
the existence of a low-resolution reconstruction of the mitoribo-
some provided important clues regarding the conservation of
gross features of the organellar particle.
The disruptive power potential was estimated for the equiva-
lent heterologous positions by the following criteria: N ¼ ‘cer-
tainly not disruptive’, supportive direct mutagenesis data in
favor of this assignment exists for the tested residue or its base-
pairing partner, U ¼ ‘unlikely disruptive’, no direct mutagen-
esis data exist but enough indirect data exist in favor of this
conclusion; NEE ¼ ‘not enough evidence’, no direct or indirect
evidence argues against a potential disruptive power; L ¼
‘likely disruptive’, no direct mutagenesis data exist but enough
indirect data exist in favor of this conclusion and C ¼ ‘certainly
disruptive’, supportive direct mutagenesis data exist for the
tested residue or its base -pairing partner. A mtDNA mutation
would be considered to have equally disruptive power to its
heterologous counterpart as long as the available structural
data for the former is not in disagreement with the heterologous
evidence, e.g. if the higher order structural elements taken into
consideration are conserved in both the mitochondrial and heter-
ologous ribosomes. Two additional categories were used to clas-
sify the mitochondrial mutations: und ¼ ‘undetermined’, no
heterologous data exist to evaluate the disruptive potential or
the existing structural differences are too large to allow the ex-
trapolation of conclusions made in the heterologous case and
E ¼ ‘expectedly disruptive’, which would contain the mito-
chondrial equivalents to residues assigned to the ‘certainly dis-
ruptive’ category in the heterologous system.
Conservation index analysis
We have devised three simple conservation indexes (Cis). CiUniv
was designed to monitor the universal conservation of the tested
residue in SSU rRNAs encompassing the whole width of the uni-
versal phylogenetic tree, i.e. archaeal, bacterial, eukaryotic
nuclear, mitochondria and chloroplast SSU rRNAs. It was
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calculated by assigning a value from 0 to 5 to the conservation
categories defined by Cannone et al. (25) (see Table 2). Ci1ry
measures the degree of primary sequence conservation around
the tested residue. It was calculated by assigning 1 point per
matched residue within a five-residue window centered on the
tested nucleotide. In addition, an extra point was assigned when-
ever the position of the heterologous residue had been predicted
by primary sequence alignment between the human and E. coli
SSU rRNA (102). Ci2ry is similar to Ci1ry but measures the
degree of secondary structure around the tested residue. To cal-
culate this index, we assumed structural equivalence between
G:U/U:G and Watson–Crick base-pairing schemes, as
assumed during the construction of phylogenetically derived
secondary-structure maps (25). Again, 1 point was assigned
per matched residue within the five-residue window, whenever
the same secondary structure was predicted in phylogenetically
derived secondary-structure maps of the human and E. coli SSU
rRNA (25). A half-a-point penalty would be in place whenever a
phylogenetically predicted mismatch was replaced by a canonic-
al or G:U/U:G base pair, or vice versa. Finally, an arbitrary com-
posite Ci was calculated as follows: CiTot ¼ (2 × CiUniv) +
(2 × Ci1ry) + Ci2ry. The weights of CiUniv and Ci1ry were
doubled to account for their higher predictive power (see
Results).
Structural analysis
The following crystal structures were obtained from rcsb (www.
rcsb.org): 2I2P and 2I2T (39), 2J02 and 2J03 (60), 1VSA and
2OW8 (103), 2Y0U (104), 2XZM (27) and 3R8N (31). Struc-
tural analysis was performed with UCSF Chimera (105) and
Phenix (106).
Figure 4 and Supplementary Material, Movie S1 were created
as follows. The position of all mutations that had equivalents in
E. coli 16S rRNA was located on the secondary-structure map of
T. thermophila SSU (27). The Tetrahymena positions were then
displayed on a 3D model of the SSU T. thermophila 18S rRNA
that had been previously superposed onto the 3D model of the
E. coli 16S rRNA with Chimera UCSF (27,106).
SUPPLEMENTARYMATERIAL
Supplementary Material is available at HMG online.
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